Arun Balakumaran, MD PhD – SAB Member Posted on 6 October 2022 by Karol Maryniowski Arun Balakumaran, MD PhD Oncologist, Scientist, SAB Members Oncologist, Scientist, and Biotechnology Executive. He is an MD, Ph.D., Board Certified in Hematology and Medical Oncology with a Master’s degree in Health Care Management at Harvard University. He has a long-standing interest in cell and gene therapy. His experience ranges from lab research, phase 1 -3 clinical development, including breakthrough designations and successful registration experiences, through medical affairs and business development. Arun began his biotech/pharma career at Amgen (NASDAQ: AMGN) where he was responsible for clinical development as Medical Director and North American Medical Led. Prior to joining Amgen, he spent 6 years with the NIH, where he was the Medical Lead for Bone Marrow Stromal Cells (MSC) Transplant Center. He joined Allogene (NASDAQ: ALLO) in the fall of 2018 and is currently the Head of Clinical Development running clinical programs in allogeneic CAR-Ts targeting CD19, BCMA, and CD70. Before Allogene, Arun was Executive Director and Product Development Lead, Hematological Malignancies at Merck (NYSE: MRK), driving the approval of Pembrolizumab in lymphomas. Additionally, he is on the scientific advisory board of diagnostic companies.